

MITOMYCIN FLUOROURACIL with concurrent radiotherapy

INDICATION (ICD10) C80

1. Bladder cancer with concurrent RT. PS 0, 1, 2

REGIMEN

Day 1 MITOMYCIN 12mg/m² (maximum 20mg) IV bolus FLUOROURACIL 2500mg/m² IV infusion over 5 days

Day 22 FLUOROURACIL 2500mg/m² IV infusion over 5 days

CYCLE FREQUENCY AND NUMBER OF CYCLES

One cycle

ANTI-EMETICS

Low emetogenic risk

CONCURRENT MEDICATION REQUIRED

Fluorouracil	Mouth and bowel support eg_Loperamide, benzydamine mouthwash		
	Prophylactic antibiotics eg ciprofloxacin 250mg bd for 6 weeks during		
	chemoradiotherapy and until skin reactions have settled		

EXTRAVASATION AND TYPE OF LINE / FILTERS

Fluorouracil - inflammitant Mitomycin - vesicant

Central line (single lumen)

INVESTIGATIONS

Blood results required before SACT administration

FBC, U&E and LFTs every cycle

Neutrophils x 10⁹/L ≥1.5

Platelets x 10⁹/L ≥100

Serum creatinine

ECG (possible ECHO) required if patient has preexisting cardiac disease

DPD test

Baseline weight and every cycle

MAIN TOXICITES AND ADVERSE REACTIONS

Fluorouracil	Palmar plantar (handfoot syndrome) causing red palms and soles – treat with			
	pyridoxine 50mg tds			
	Diarrhoea – treat with loperamide or codeine			
	Cardiotoxicity – monitor cardiac function. Special attention is advisable in			
	treating patients with a history of heart disease, arrhythmias or angina			
	pectoris or those who develop chest pain during treatment with fluorouracil.			
	Stomatitis			

INTERACTIONS WHICH MAY REQUIRE DOSE MODIFICATIONS

(not exhaustive list check SPC/BNF/Stocklevs)

	not oxinadotive not eneck of expliniteteetkieje				
Ī	Fluorouracil	Cimetidine slightly increases exposure to fluorouracil			
		Metronidazole increased toxicity			
		Phenytoin concentration increased			
		Warfarin			

Mitomycin Fluorouracil with	Urology CAG approval	Page 1 of 2	Approved: December 2021	Version
RT				5.0



DOSE MODIFICATIONS

Mitomycin maximum lifetime dose = 60mg/m²

Fluorouracil

The fluorouracil course should be delayed for a week or until completely recovered in the event of either low blood counts (neutrophils <1.5x10⁹ or platelets <100x10⁹) or any persistent mucositis or diarrhoea.

Non-haematological toxicity (CTC	0-1	2	3	4
grade): diarrhoea, stomatitis				
Haematological toxicity (x10 ⁹ /L):	100%	80%	50%	No further
Platelets ≥50 and neutrophils ≥1.0				treatment
Haematological toxicity (x10 ⁹ /L):	80%	70%	50%	No further
Platelets 25-49 or neutrophils 0.5-0.9				treatment
Haematological toxicity (x10 ⁹ /L):	50%	50%	50%	No further
Platelets <25 or neutrophils <0.5				treatment

Hepatic impairment

Fluorouracil

Significantly impaired hepatic function eg bilirubin >50micromol/L may be a sign of disease progression and require cessation of, or change in, treatment. Always discuss deteriorating liver function with consultant.

Bilirubin >85micromol/L	not recommended

Renal impairment

Fluourouracil

CrCl >30ml/min	Give 100% dose
CrCl <30ml/min	Consider dose reduction

Mitomycin

CrCl ≥30ml/min	give 100% dose
CrCl <30ml/min	not recommended

REFERENCES

Mitomycin Fluorouracil with	Urology CAG approval	Page 2 of 2	Approved: December 2021	Version
RT				5.0